Atorvastatin vs Simvastatin: Number of Participants With Post-index Cardiovascular (CV) Events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measure	Value	95% interval, lower	95% interval, upper	Method	Source
Risk in group 1	0.061	0.0568	0.0656	wilson	ClinicalTrials.gov
Risk in group 2	0.0503	0.0473	0.0534	wilson	ClinicalTrials.gov
Risk difference, group 1 minus group 2	0.0108	0.00551	0.0162	newcombe hybrid score	ClinicalTrials.gov
Risk ratio, group 1 over group 2	1.21	1.11	1.33	log	ClinicalTrials.gov
Odds ratio, group 1 over group 2	1.23	1.11	1.36	log	ClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on Atorvastatin than on Simvastatin	92.9	61.9	182	from the risk difference interval	ClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

Group	Title	Description	With the outcome	Analysed	ClinicalTrials.gov code	Source
Group 1	Atorvastatin	Participants who had been on atorvastatin with dose strength ranging from 10 milligram (mg) to 80 mg were observed for 12 months and a 3 month follow-up period.	700	11,470	OG000	ClinicalTrials.gov
Group 2	Simvastatin	Participants who had been on simvastatin with dose strength ranging from 5 mg to 80 mg were observed for 12 months and a 3 month follow-up period.	1,012	20,132	OG001	ClinicalTrials.gov

Outcome 5

Field	Value	Source
Type	PRIMARY	ClinicalTrials.gov
Title	Number of Participants With Post-index Cardiovascular (CV) Events	ClinicalTrials.gov
Description	CV events were defined as an inpatient or emergency department admission for heart failure (HF), myocardial infarction (MI), ischemic heart disease (IHD), cerebrovascular disease, peripheral vascular disease (PVD), aortic aneurysm, and/or revascularization. CV events were identified using medical claims.	ClinicalTrials.gov
Time frame	At least 3 months from the post-index date (baseline) or end of study (28 February 2009)	ClinicalTrials.gov
Population	Evaluable analysis population included all participants who met inclusion criteria.	ClinicalTrials.gov

Trial 8

Field	Value	Source
Title	Cardiovascular Events Based On Statin Initiation In The Elderly	ClinicalTrials.gov
NCT number	NCT01304641	ClinicalTrials.gov
Phases		ClinicalTrials.gov
Conditions	Cardiovascular, Dyslipidemia	ClinicalTrials.gov
Interventions	Atorvastatin Initiators, Simvastatin Initiators	ClinicalTrials.gov
Lead sponsor	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	ClinicalTrials.gov
Results first posted	2012-04-05	ClinicalTrials.gov
Results on ClinicalTrials.gov	https://clinicaltrials.gov/study/NCT01304641?tab=results	ClinicalTrials.gov

Source 4

Field	Value	Source
Release	trial-comparisons-2026-03-23-0.1.0	ClinicalTrials.gov
Release manifest SHA-256	f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57	ClinicalTrials.gov
AACT copy	2026-03-23	ClinicalTrials.gov
Tables read	outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet	ClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.